1548 — Genscript Biotech Share Price
0.000.00%
Last trade - 00:00- HK$22.52bn
- HK$19.04bn
- $594.49m
- 17
- 29
- 98
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.45 | ||
| PEG Ratio (f) | 0.18 | ||
| EPS Growth (f) | 388.95% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.67 | ||
| Price to Tang. Book | 0.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.27% | ||
| Return on Equity | -2.35% | ||
| Operating Margin | -27.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 390.85 | 490.1 | 625.7 | 560.48 | 594.49 | 904.23 | 803.58 | 16.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | -26.73 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genscript Biotech Corp is a company primarily engaged in bioscience research and related businesses. The Company operates through four segments. The Life-Science Services and Products segment provides comprehensive reagent services and products, instruments and custom-tailored solutions for gene therapy, cell therapy, antibody therapeutics, vaccines and diagnostics. The Biologics Development Services segment provides comprehensive services aimed to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment provides industrial enzyme development and production by non-pathogenic microbial strains constructed using genetic engineering. The Cell Therapy segment is engaged in the discovery and development of novel cell therapies for oncology and other indications.
Directors
- Jiange Meng CHM (52)
- Ye Wang PRE (52)
- Liu Zhenyu CEO (44)
- Shiniu Wei CFO (42)
- Huang Ying CEX (48)
- Li Zhu EDR (71)
- Wai Ling Wong SEC
- Yuexin Pan NED (62)
- Jiafen Wang NED (69)
- Luquan Wang NED (51)
- Zumian Dai NID (43)
- Hongxin Guo NID (57)
- Jiuan Pan NID (52)
- Xuehai Wang NID (46)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 21st, 2015
- Public Since
- December 30th, 2015
- No. of Employees
- 5,568
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 2,165,058,787
- Address
- No. 28, NANJING
- Web
- https://www.genscript.com
- Phone
- +86 2558897288
- Auditors
- Ernst & Young CPA
Upcoming Events for 1548
Genscript Biotech Corp Annual Shareholders Meeting
Half Year 2025 Genscript Biotech Corp Earnings Release
Similar to 1548
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
What is the Genscript Biotech share price?
As of Today at 20:47 UTC, shares in Genscript Biotech are trading at HK$10.40. This share price information is delayed by 15 minutes.
How has the Genscript Biotech share price performed this year?
Shares in Genscript Biotech last closed at HK$10.40 and the price had moved by -9.57% over the past 365 days. In terms of relative price strength the Genscript Biotech share price has underperformed the FTSE Developed Asia Pacific Index by -6.99% over the past year.
What are the analyst and broker recommendations for Genscript Biotech?
The overall consensus recommendation for Genscript Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Genscript Biotech dividend yield?
Genscript Biotech does not currently pay a dividend.
Does Genscript Biotech pay a dividend?
Genscript Biotech does not currently pay a dividend.
When does Genscript Biotech next pay dividends?
Genscript Biotech does not currently pay a dividend.
How do I buy Genscript Biotech shares?
To buy shares in Genscript Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Genscript Biotech?
As of the previous close price of HK$10.40, shares in Genscript Biotech had a market capitalisation of HK$22.52bn.
Where are Genscript Biotech shares listed?
Here are the trading details for Genscript Biotech:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1548
What kind of share is Genscript Biotech?
Based on an overall assessment of its quality, value and momentum Genscript Biotech is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Genscript Biotech share price forecast for 2025?
The analyst consensus target price for shares in Genscript Biotech is HK$23.14. That is 122.47% above the last closing price of HK$10.40.
Analysts covering Genscript Biotech currently have a consensus Earnings Per Share (EPS) forecast of $0.10 for the next financial year.
Find out moreWhat is the trend in the Genscript Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genscript Biotech. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -5.65%.
As of the last closing price of HK$10.40, shares in Genscript Biotech were trading -9.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Genscript Biotech PE Ratio?
The Genscript Biotech PE ratio based on its reported earnings over the past 12 months is 14.45. The shares last closed at HK$10.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Genscript Biotech?
Genscript Biotech's management team is headed by:
- Jiange Meng - CHM
- Ye Wang - PRE
- Liu Zhenyu - CEO
- Shiniu Wei - CFO
- Huang Ying - CEX
- Li Zhu - EDR
- Wai Ling Wong - SEC
- Yuexin Pan - NED
- Jiafen Wang - NED
- Luquan Wang - NED
- Zumian Dai - NID
- Hongxin Guo - NID
- Jiuan Pan - NID
- Xuehai Wang - NID